EHMT2 and non-small cell lung carcinoma: In NSCLC, upregulation of EHMT2 leads to downregulation of phosphatase and tensin homolog (PTEN), promoting activation of the AKT pathway and consequently facilitating resistance to EGFR-TKI (40).